Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio ...

Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by key opinion leader, Professor Jacky Smith Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto ...

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients ...